The Latest Breaking News from Lilly

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.

Twitter's new verification system shook Eli Lilly — leading LLY stock to skid Friday — after a fake account claimed "insulin is free now."

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

An analysis of major companies’ donations, including Meta and Amazon, reveals donations to candidates calling for banning the procedure

Eli Lilly topped third-quarter expectations Thursday, but cut its 2022 outlook, citing exchange rates and tax law. LLY stock tumbled.

A surging U.S. dollar and increasing generic competition combined for another disappointing outlook for drugmaker Eli Lilly, offsetting stronger-than-expected third quarter earnings.

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…